All In Biotech

NDA 209115 · Pharmaand

Rubraca

Rucaparib Camsylate · Oral

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Dec 19, 2016

Approved uses

8

Original approval plus efficacy supplements

Registered trials

7

1 Phase 3, 0 recruiting

FAERS reports

8,796

3,821 serious, 510 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 16, 2026.

RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. 1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )]. 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a...

Mechanism: Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. In vitro studies have shown that rucaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cancer cell death. Increased rucaparib-induced cytotoxicity and anti-tumor activity was observed in tumor cell lines with deficiencies in BRCA1/2 and other DNA repair genes. Rucaparib has been shown to decrease tumor growth in mouse xenograft models of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 17, 2025 Supplement 15 · Efficacy LetterLabel
  • Dec 17, 2025 Supplement 14 · Efficacy LetterLabel
  • Dec 21, 2022 Supplement 13 · Efficacy · priority review LetterLabel
  • Jun 10, 2022 Supplement 11 · Efficacy · priority review LabelLetter
  • Oct 8, 2020 Supplement 8 · Efficacy · priority review LetterLabel
  • May 15, 2020 Supplement 4 · Efficacy · priority review Breakthrough therapyLabelLetter
  • Apr 6, 2018 Supplement 3 · Efficacy · priority review OrphanLabelLetter
  • Dec 19, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
3 products under this application
  • RUBRACA · RUCAPARIB CAMSYLATE EQ 250MG BASE · TABLET, ORAL · Prescription
  • RUBRACA · RUCAPARIB CAMSYLATE EQ 200MG BASE · TABLET, ORAL · Prescription
  • RUBRACA · RUCAPARIB CAMSYLATE EQ 300MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rucaparib Camsylate" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,553
  • nausea2,263
  • malignant neoplasm progression1,184
  • decreased appetite802
  • diarrhoea790
  • constipation785
  • vomiting784
  • asthenia681
  • adverse event571
  • carbohydrate antigen 125 increased571
  • dysgeusia567
  • anaemia557

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
20171,423
20181,516
20191,834
20201,442
20211,057
2022889
2023183
2024243
2025137
202670

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rubraca (Rucaparib Camsylate)

2024 spending

$31.5M

Beneficiaries

396

2,278 claims

Per beneficiary

$79,573

$144.47 per unit

View as table
YearSpending
2020$70,706,784
2021$64,385,480
2022$49,037,919
2023$43,036,982
2024$31,510,916

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Pharmaand

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.